PLASMINOGEN-ACTIVATOR OF UROKINASE-TYPE AND ITS INHIBITOR OF PLACENTAL TYPE IN HYPERTENSIVE PREGNANCIES AND IN INTRAUTERINE GROWTH-RETARDATION - POSSIBLE MARKERS OF PLACENTAL FUNCTION

被引:29
作者
LINDOFF, C
ASTEDT, B
机构
[1] Department of Obstetrics and Gynecology, Research Laboratory
关键词
FIBRINOLYSIS; UROKINASE; PLASMINOGEN ACTIVATOR INHIBITOR; PREGNANCY; PLACENTA;
D O I
10.1016/S0002-9378(94)70078-8
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: Our purpose was to study the plasma concentrations of the plasminogen activator of urokinase type and its specific inhibitor of placental type in pregnancies complicated by hypertension or fetal growth retardation. STUDY DESIGN: Consecutive patients with pregnancy-induced hypertension (n = 17), mild preeclampsia (n = 17), severe preeclampsia (n = 19), and intrauterine growth retardation (n = 19) were studied. Blood samples were obtained just before delivery (mean 2 days). Women with normal pregnancies (n = 40), longitudinally followed between the tenth and fortieth gestational weeks, served as a control group. RESULTS: The plasma concentrations of the urokinase type antigen were significantly lower in women with severe preeclampsia or intrauterine growth retardation than those in women with normal pregnancies (p < 0.001). In all four groups with complicated pregnancies the antigen concentrations of the urokinase type and its inhibitor were significantly correlated with both placental weight and birth weight. CONCLUSIONS: The plasma concentration of the urokinase type antigen would appear to reflect placental function, and both the antigen and its inhibitor concentrations are correlated with placental and fetal growth.
引用
收藏
页码:60 / 64
页数:5
相关论文
共 30 条
[1]   IMMUNOLOGICAL IDENTITY OF UROKINASE AND OVARIAN CARCINOMA PLASMINOGEN ACTIVATOR RELEASED IN TISSUE-CULTURE [J].
ASTEDT, B ;
HOLMBERG, L .
NATURE, 1976, 261 (5561) :595-597
[2]  
ASTEDT B, 1986, THROMB HAEMOSTASIS, V56, P63
[3]  
ASTEDT B, 1987, Fibrinolysis, V1, P203, DOI 10.1016/0268-9499(87)90037-3
[4]  
ASTEDT B, 1972, J OBSTET GYN BR COMM, V79, P205
[5]  
Binder B R, 1990, Blood Coagul Fibrinolysis, V1, P717
[6]   FIBRINOLYTIC ENZYME SYSTEM AND PREGNANCY [J].
BONNAR, J ;
MCNICOL, GP ;
DOUGLAS, AS .
BMJ-BRITISH MEDICAL JOURNAL, 1969, 3 (5667) :387-+
[7]   COAGULATION AND FIBRINOLYTIC MECHANISMS DURING AND AFTER NORMAL CHILDBIRTH [J].
BONNAR, J ;
MCNICOL, GP ;
DOUGLAS, AS .
BRITISH MEDICAL JOURNAL, 1970, 2 (5703) :200-&
[8]   FIBRINOLYTIC SYSTEM IN HUMAN BLOOD DURING PREGNANCY [J].
BRAKMAN, P .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1966, 94 (01) :14-&
[9]   PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].
DANO, K ;
ANDREASEN, PA ;
GRONDAHLHANSEN, J ;
KRISTENSEN, P ;
NIELSEN, LS ;
SKRIVER, L .
ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266
[10]   PLACENTAL-TYPE PLASMINOGEN-ACTIVATOR INHIBITOR IN PREECLAMPSIA [J].
DEBOER, K ;
LECANDER, I ;
TENCATE, JW ;
BORM, JJJ ;
TREFFERS, PE .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1988, 158 (03) :518-522